Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin and Dapagliflozin Add-on to Metformin in T2DM
NCT02681094Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of saxagliptin and dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in HbA1c at Week 24. Started Feb 2016; status: completed.
02
Drugs
saxagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02681094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681094.